About
CohBar is a clinical-stage biotechnology company focusing on developing breakthrough therapeutics targeting chronic and age-related diseases with minimal or no current treatment options by leveraging the power of the mitochondria and its encoded peptides within its genome. With an expert team of scientists in mitochondrial biology, broad IP coverage, key opinion leaders and a disciplined drug discovery and development process, CohBar has become a leader in exploring the mitochondrial genome and its utility for development of novel therapeutics.